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Abstract
Background: Mammary stem cells have been extensively studied as a system to delineate the pathogenesis and treatment
of breast cancer. However, research on mammary stem cells requires tissue biopsies which limit the quantity of samples
available. We have previously identified putative mammary stem cells in human breast milk, and here, we further
characterised the cellular component of human breast milk.
Methodology/Principal Findings: We identified markers associated with haemopoietic, mesenchymal and neuro-epithelial
lineages in the cellular component of human breast milk. We found 2.660.8% (mean6SEM) and 0.760.2% of the whole cell
population (WCP) were found to be CD133+ and CD34+ respectively, 27.869.1% of the WCP to be positive for Stro-1
through flow-cytometry. Expressions of neuro-ectodermal stem cell markers such as nestin and cytokeratin 5 were found
through reverse-transcription polymerase chain reaction (RT-PCR), and in 4.1760.2% and 0.960.2% of the WCP on flow-
cytometry. We also established the presence of a side-population (SP) (1.860.4% of WCP) as well as CD133+ cells (1.760.5%
of the WCP). Characterisation of the sorted SP and non-SP, CD133+ and CD133- cells carried out showed enrichment of
CD326 (EPCAM) in the SP cells (50.668.6 vs 18.166.0, P-value =0.02). However, culture in a wide range of in vitro conditions
revealed the atypical behaviour of stem/progenitor cells in human breast milk; in that if they are present, they do not
respond to established culture protocols of stem/progenitor cells.
Conclusions/Significance: The identification of primitive cell types within human breast milk may provide a non-invasive
source of relevant mammary cells for a wide-range of applications; even the possibility of banking one’s own stem cell for
every breastfeeding woman.
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Introduction
The mammary gland is metabolically active, and has the capacity
to undergo cycles of extensive proliferation and hypertrophy in
order to meet the needs of pregnancy, lactation and involution. In
order to support this activity, the presence of mammary stem cells
(MaSC) which have the ability to give rise to different components
of the lactation machinery have been proposed.
The existence of MaSC was first demonstrated nearly five
decades ago with the successful reconstitution of the entire murine
mammary gland through the transplantation of non-sorted mam-
mary epithelium into cleared fat pads [1], although the identity of
the components of the epithelium transplanted wasn’t well
defined. More recently, Gudjonsson et al, using well characterised
immortalized cell lines from human breast tissues, demonstrated
that these mammary stem cells are derived from the suprabasal
compartment of the ductal epithelium in human breast [2]. This
was followed closely by the description of a serum-free spheroid
culture system which enriches for MaSC that demonstrated self-
renewal and the capacity to differentiate into terminal ductal
lobular units (TDLU) when placed into matrigel-coated plates,
allowing their culture and in vitro behavior to be studied [3].
The prospective isolation of MaSC capable of reconstituting
mammary glands was first demonstrated by Alvi et al, who
identified these cells by their ability to exclude Hoechst dye [4].
Finally, Shackleton et al demonstrated the reconstitution of an
entire mammary gland from a single lineage negative, CD29hi and
CD49
+ murine mammary cell, which were capable of generating
secondary clonal outgrowths in serial transplantation experiments,
conclusively demonstrating the existence of MaSC [5].
The derivation of both normal MaSC [3], [5] and breast cancer
stem cells [6], [7] should allow the delineation of molecular
pathways implicated in breast cancer oncogenesis and prognosti-
cation applications [8].
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luminal cavities, there have been few studies documenting their
presence in luminal discharges. In the gastro-intestinal system,
stem cells have been localized to the basal crypts [9], [10],
although there have been no reports of these epithelial stem cells
being shed into the gastrointestinal tract. Similarly, it has been
proposed that the epithelial stem cells reside in the niche at the
base of the glands in the endometrium [11], and shown to be
present just beneath the luminal epithelium and in the
endometrial-myometrial junction [12], [13]. More recently,
mesenchymal progenitor cell types have been isolated through
the collection of human menstrual blood as well as human breast
milk (HBM) [14], [15], [16]. In the bladder, rare stem/progenitor
cell types from the epithelial, urothelial and smooth muscle lineage
have been identified at a clonal level, with the capacity for self-
renewal and multi-lineage differentiation [17].
Breast milk comprises epithelial cells, colostral corpuscles,
polymorphonuclear leukocytes, mononuclear phagocytes and
lymphocytes [18], [19], with those of epithelial lineage forming
the main bulk of cells within two weeks of establishing lactation
[20]. We hypothesised that these epithelial cells are shed from the
ductal and luminal epithelial layers through either a heightened
turnover of the secretory tissue, or as a consequence of the
mechanical shear forces associated with the continued filling and
emptying cycle associated with breast milk synthesis and lactation.
We have previously identified putative MaSC from HBM through
their expression of various cytokeratin (CK) markers, CK5, 14 and
19 and nestin [21], but have yet to establish other hallmarks of
stem/progenitor cells. In this study, we isolated putative stem cell
populations in HBM, and characterise their potential to self-renew
and differentiate down various lineages, in order to establish their
identity as stem/progenitor cells.
Results
Breast milk contains a heterogeneous population of cells
derived from various lineages
The cell concentration in milk ranges widely from 1610
3 to
8610
5 cells per ml of milk, which was not related to the duration
of lactation (r
2=0.03, Fig. 1). The cellular components included a
heterogenous population of cells comprising neutrophils, lympho-
cytes, monocytes, lactocytes and macrophages as was previously
described [22]. In order to further characterise this heterogeneous
cellular population of HBM, we looked for lineage specific markers
in this mixed cell population at the mRNA and protein level in
freshly isolated, uncultured WCP from HBM.
Haemopoietic stem cell markers exists in uncultured
WCP in HBM
First, we looked for the presence of haemopoietic stem/
progenitor cell types through the presence of CD34, a well known
haemopoietic stem cell marker [23], and CD133, which is
associated with haemopoietic as well as neural stem/progenitor
cells [24], [25]. Reverse transcription polymerase chain reaction
(RT-PCR) demonstrated the presence of CD34 and CD133
mRNA transcripts in all three WCP samples examined, but not in
a breast adenocarcinoma cell line, MCF-7 (Fig. 2a). Flow
cytometry performed in a separate experiment (n=4) showed a
mean of 2.6 6 0.79% and 1.1 6 0.15% of the WCP being CD133
and CD34 positive respectively (Table 1).
Cells of mesenchymal lineages exist in uncultured WCP in
HBM
Next, we looked for the presence of mesenchymal lineages in
WCP. We found that transcripts for osteonectin, alkaline
phosphatase and osteopontin, relating to osteogenic differentia-
tion, were expressed in all samples tested (n=3) (Fig. 2b) [26]. In
addition, flow cytometry demonstrated the presence of Stro-1, a
well known marker for mesenchymal stem cells (MSC) [27], in
27.8 6 9.13% of the WCP (n=3), suggesting that mesenchymal
osteo-progenitors may reside within this mixed population.
Neuro-epithelial lineage in uncultured WCP in HBM
Finally, we looked for the presence of transcripts associated with
neuro-epithelial tissues in WCP. We found uniform expression of
nestin, an early neural progenitor marker, in all samples
examined, but only one out of three samples expressing both
Musashi-1 (Msi-1) [28] and neurofilament M (NFM) [29] (Fig. 2c),
markers of early and late neural differentiation respectively. This
suggested the presence of both differentiated and undifferentiated
neuro-progenitor cell types in this sample.
Cytokeratin (CK) 5, CK14 and CK18 are established markers
used to delineate the degree of differentiation of mammary
epithelial cells. CK5 is a marker for mammary progenitor cells,
CK14 is a marker for both mammary progenitor cells and mature
myoepithelial cells and CK18 is an established marker for mature
luminal epithelial cells [30]. RT-PCR of WCP demonstrated
universal expression of CK5, CK14 and CK18 in all samples
examined (n=3) (Fig. 2d).
Side-population of HBM is enriched for primitive cell
markers
We next determine the proportion of cells that are able to
exclude Hoechst 33342 dye in 47 mothers, and explored their
capacity for self-renewal and differentiation. We found the
existence of a SP in 40 out of 47 milk donors (85.1%) (Fig. 3a),
at a frequency of 2.0660.33%, which was not related to either the
duration of breastfeeding or age of the mother (Fig. 3b, c). After
flow-sorting SP and non-SP (NSP) cells, the sorted cells were
stained for the expression of various epithelial and non-epithelial
markers (Table 2).
The mature marker CK18 was expressed by a larger proportion
of cells in non-SP compared to SP cells (39.4 6 9.8% NSP vs. 5.3
6 4.0% NSP cells, p,0.05), while there was a higher occurrence
of primitive nestin+ cells in the SP over the NSP population (90 6
4.7% of SP vs 0.67 6 0.54% of non-SP, p,0.001) (Fig. 4d).
EPCAM, which is known to be expressed by bi-potent mammary
Figure 1. Cellular concentration in human breast milk did not
vary in relation to the duration of breastfeeding.
doi:10.1371/journal.pone.0014421.g001
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and EPCAM- myoepithelial progenitors [31], [32], was found to
be enriched in the SP fraction (50.668.6% vs 18.166.0%,
p=0.02). We found a small increase in CD31+ cells in the SP
(1.96.2% vs. 0.760.3%, p=0.04) over the NSP fraction, which
may indicate the presence of haemopoietic and/or endothelial
cells, which are known to express CD31 [33], within the SP
(Table 2).
Side-population of HBM did not contain mammary stem
cells or haemopoietic stem/progenitor cells or
mesenchymal stem cells
In order to better define putative stem/progenitor cells, we
attempted to culture SP fraction as mammospheres or serum-free
spheroid culture system, which has been largely used to define the
self-renewal capacity of MaSC in both normal and malignant
mammary tissues [3], [34], [35], [36], [37], [38], [39]. Despite
plating SP cells at a range of plating densities, addition of varying
concentrations of growth factors (20–00 ng/ml of EGF and bFGF)
and using the aid of different substratum, no mammospheres was
observed (See supplementary data). On the other hand, serum-free
culture of the SP (Fig. 4a) and not the NSP of a breast carcinoma
cell line, MCF-7 resulted in the generation of free-floating
mammospheres (Fig. 4b). These MCF-7 SP derived mammo-
spheres stained positive for CD49f, EPCAM, CK18, CK14, CK5
and CK19, and negative for CD45 and CD10, an immunophe-
notype consistent with MaSC cultured as mammospheres (Fig. 4c).
As the SP fraction in bone marrow is enriched for haemopoietic
stem cells [40], we next interrogated HBM for the presence of
haemopoietic stem cell types by culturing SP and NSP fractions of
HBM in a methylcellulose culture system. However, we did not
find the expansion of any haemopoietic colonies (n=5) in either
SP or NSP fraction from HBM, while we observed the
development of multi-lineage colony forming units (CFU) from
the SP fraction of umbilical cord blood (Fig. 4e). Thus, both the SP
and NSP fractions of HBM did not contain any haemopoietic
progenitors that behave in the typical manner of haemopoietic
progenitors.
Next, we investigated whether the SP or NSP fractions enriched
for putative MSC in HB (n=3 individual samples) [16].
Figure 2. RT-PCR on Messenger RNA (mRNA) of milk samples from three individuals. (a) mRNA of CD133 and CD34 were present in WCP
of HBM (Lane 1–3). (b) Osteonectin (ON), alkaline phosphatase (ALP) and osteopontin (OP) (Lane 1–3) as well as (c) musashi-1 (Msi), nestin (NES) and
neurofilament-M (NFM) in observed in WCP of HBM (Lane 1–3). (d) Messenger RNA of CK5, 14 and 18 were present in WCP of HBM (Lane 1–3). The
negative controls in Lane 4, were MCF-7 for hematopoietic, mesenchymal and neural markers [49] and mononuclear cells in peripheral blood for
epithelial cell markers of CK5 and CK14. Positive controls (Lane 5) are cells isolated from umbilical cord blood (a), fetal MSC (b), cells from snap-frozen
fetal brain (c) and MCF-7 (d) respectively.
doi:10.1371/journal.pone.0014421.g002
Table 1. Antigens expressed on the cells in HBM.
Antigen Name
Expression determined by Flow
Cytometry
Mean (%)
No. of
Samples S.E.M.
CD133 Prominin-like 1 2.6 4 0.8
CD117 c-kit 0.0 3 0.0
CD24 BA-1 70.7 3 10.3
CD29 b-1 Integrin 11.5 3 5.8
CD49f A-6 Integrin 11.4 3 7.3
CDw338 ABCG2 21.1 3 1.8
CD34 0.7 3 0.3
Stro-1 27.8 3 9.1
Nestin 4.7 3 0.2
doi:10.1371/journal.pone.0014421.t001
Stem Cells in Breast Milk
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and Stro-1, we found no differences between the two fractions in
their expression of CD73, CD105 and Stro-1 (Table 2). We also
investigated the ability of the two fractions to give rise to colony-
forming unit-fibroblast (CFU-F), alongside the positive control of
human fetal MSC. Only human fetal MSC were able to form
adherent colonies in standard MSC CFU-F assay (Fig. 5a, b) and
differentiated down the osteogenic pathway as evidenced by the
accumulation of extracellular calcium crystals stained positively
with Alizarin Red and Von Kossa (Fig. 5c, d), but not in either SP
or NSP fractions from HBM of three individuals (Fig. 5e).
CD133-positive cells of HBM did not contain mammary
stem cells or haemopoietic stem/progenitor cells
CD133 has been associated with several different primitive cell
populations, such as haemopoietic, neural, endothelial stem/
progenitor cells, and other primitive cells [42]. Since it is a primitive
cell marker present on haemopoietic and neuro-ectodermal stem/
progenitor cells [24], [25], we hypothesised that the putative stem
cells in HBM may be found in the CD133 fraction of HBM. We
found that 2.060.003% (n=23) of the cellular component in HBM
are CD133+ (Fig. 6a), which was unaffected by either the maternal
age or the duration of breastfeeding (Fig. 6b, c).
CD133+ HBM cells did not demonstrate any significant
differences in their expression of EPCAM, CD34, CD45, lineage
and CD105 with CD133- HBM cells (Table 3). When plated onto
methylcellulose cultures for haemopoietic assays, umbilical cord
blood CD133+ cells, and not HBM CD133+ cells, demonstrated
multi-lineage haemopoietic colony forming capacity (Fig. 6d). Both
CD133+ and CD1332 HBM cells did not generate any
mammospheres in serum free growth conditions.
Mensenchymal culture of cells in HBM
In order to isolate putative MSC from HBM, we pursued two
approaches. Firstly, WCP from HBM (n=4) was plated in MSC
growth medium (D10) at densities of 5610
4 to 14610
4 cells per
cm
2, with half medium change every four days. In contrast to
human fetal MSC controls, which generated adherent colonies
over 14 weeks of culture and differentiated into osteoblasts staining
positive with Alizarin Red and Von Kossa, no adherent cultures
were seen in the WCP (Fig. 5f).
Next we attempted to enrich the putative MSC cells from WCP
through expression of the osteoprogenitor marker Stro-1 by flow
cytometry (n=3). We did not select Stro-1 cells from the SP
fraction as there was no difference in the frequency of Stro-1
positive cells in either SP or NSP fraction (Table 2). Both Stro-1
positive and negative cells from WCP of HBM were seeded in D10
at a cell density ranging from 10610
3 to 36610
3 to cells per cm
2.
However, no fibroblastic adherent colonies were established
(Fig. 5g). Colony-forming unit assays with either Stro-1 positive
or negative cells showed no formation of colonies (Fig. 5h).
Discussion
Here, we demonstrated that cells with markers associated with
haemopoietic, mesenchymal as well as neuro-epithelial lineages
are found in the cellular component of HBM. The findings of the
numerous markers associated with haemopoietic, mesenchymal
and neuro-epithelial markers at both mRNA and protein level
confirmed the heterogeneity of uncultured HBM. The positive
findings of CK5, CK14 and CK18 mRNA transcripts in all 3 of
the samples tested contrasted with our previous data in which
CK5 was not identified in WCP, but was expressed only after two
weeks of in vitro culture in lactocyte medium till confluency [21].
As these three markers are well-established to delineate the varying
stages of differentiation [30], we proposed that the disparity
observed is likely to be due to the highly heterogenous nature of
HBM, as illustrated earlier by the differential expression of neural
markers, Msi-1 and NFM.The positive expression of various
primitive stem/progenitor cell markers like CD133, Stro-1, nestin
and the presence of SP within the WCP of HBM, suggests that
expressed HBM may be a novel source of putative stem/
progenitor cells. If proven, these valuable cells can be obtained
non-invasively from lactating women, thereby creating a plentiful
and ethically acceptable source of stem cells for use in a wide-
range of mammary gland and stem cell biology applications.
Using the above stem/progenitor cell markers, we attempted to
establish the presence of haemopoietic, mammary and mesenchy-
mal stem cells through a range of well controlled culture
conditions. However, we had been unable to culture any of these
cells, which may reflect still suboptimal culture systems employed
here, and may require in vivo models for further studies.
Satish et al, found a very high expression of 96.8% of CD29+
cells in the cellular component of HBM after they have been
passaged in DMEM between two to six times while observing a
comparatively lower expression of CD29 expressed by 10–15% of
cells directly isolated from HBM [16], which is similar to our data.
This indicated that either their culture conditions favoured the
growth of the mesenchymal cells present or it coerced the CD29-
cells to express b1integrin. We found markers of mesenchymal
cells through the presence of Stro-1 in a quarter of cells in WCP of
HBM and positive mRNA expression of osteonectin, alkaline
phosphatase and osteopontin through RT-PCR. However, under
carefully controlled conditions, we were unable to establish any
adherent colonies despite either plating WCP or selected Stro-1
Figure 3. Side-population of HBM. (a) Sorting profile of side-population (SP) and non side-population (NSP) from breast milk. (b) Scatter plots
showing no relationship between the percentage of SP and duration of breastfeeding and (c) age of mother. (d) Immunocytochemistry illustrating
expression of nestin exclusively only on SP (top left) and expression of CK 18 exclusively on NSP (bottom right).
doi:10.1371/journal.pone.0014421.g003
Table 2. Antigens expressed on the SP and NSP in HBM.
Properties Antigen
Expression
on SP
Expression
on NSP P-value
CD44 5.962.4 23.3610.0 0.25
Mammary CD24 47.1619.1 37.5617.7 0.42
Stem Cell CD29 0.360.2 2.761.9 0.36
CK5 9.464.4 12.066.0 0.79
Mammary CD10 3.962.3 1.760.7 0.53
Epithelial Cell EPCAM 50.668.6 18.166.0 0.02*
CD45 5.762.3 12.764.6 0.25
Lin 37.8617.8 5.761.5 0.29
Non- CD105 27.969.9 6.564.4 0.32
Epithelial CD31 1.960.2 0.760.3 0.04*
Stro-1 11.568.7 2.160.8 0.38
CD73 0.160.04 0.060.04 0.30
doi:10.1371/journal.pone.0014421.t002
Stem Cells in Breast Milk
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high densities as compared to human fetal MSC.
The differences between Satish et al and our findings could be
due to different culture conditions employed, such as the use of
allogeneic human serum in contrast to our use of fetal bovine
serum used routinely for culture of MSC in our laboratory [43],
[44], [45]. Alternatively, the starting source of HBM may account
for the differences observed here as Satish et al had isolated MSC
from HBM obtained within five days of delivery while we utilised
more mature milk between one to twelve months of delivery.
Therefore, it is possible that the MSCs are shed into HBM in the
earlier phase of lactation, but may not be present later on when
Figure 5. Mesenchymal Culture of Cells. (a, b) Adherent colonies of fetal MSC emerged after low density seeding at 4 cells per cm
2. Osteogenic
induction of fetal MSC resulted in the deposition of extracellular calcium crystals staining positive with Alizarin red (c) and Von Kossa (d).CFU-F assays
of SP and NSP as well as Stro1 positive and negative fractions of HBM did not establish any colonies as shown by the absence of colonies (e, h). WCP
(f) and Stro-1 positive cells (g) cultured in D10 remained as non-adherent cells (red arrows) which did not undergo any proliferation in culture.
doi:10.1371/journal.pone.0014421.g005
Figure 4. Culture of SP of positive control. (a) Flow cytometry profile of MCF-7, a breast cancer cell line from which the side population which
was sorted out (b) grew into mammospheres after 10 days with (c) immunocytochemistry of the mammospheres ascertaining their identity. (d) Flow
cytometry profile of umbilical cord blood with the side-population sorted out for culture in methylcellulose, (e) confirming the presence of burst
forming unit-erythrocyte (BFU-E), colony forming unit-erythrocyte (CFU-E), colony forming unit-macrophage (CFU-M), colony forming unit-
granulocyte, erythrocyte, macrophage, megakaryocyte (CFU-GEMM) as well as colony forming unit-granulocyte, macrophage (CFU-GM) in the SP of
cord blood.
doi:10.1371/journal.pone.0014421.g004
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Properties Antigen Expression on CD133+ Expression on CD1332 P-value
Mammary EPCAM 1.961.0 1.360.5 0.63
CD45 4.261.9 8.262.1 0.21
Non- Lin 0.560.2 1.160.6 0.36
Epithelial CD105 2.861.3 11.761.8 0.06
CD31 060 0.4860.4 0.36
doi:10.1371/journal.pone.0014421.t003
Figure 6. CD133 Sorting. (a) Flow cytometry of CD133 staining on cellular component of HBM (i), as compared to the isotype control (ii). (b, c)
Three was no relationship between the frequency of CD133 cells and the duration of breastfeeding, nor the age of the mother. (d) CD133+ cells from
cord blood formed multi-lineage colonies on CFC assays.
doi:10.1371/journal.pone.0014421.g006
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source of these putative MSC may be the myoepithelial cells
through the combined findings of CK5 [21] and smooth muscle
actin [16] separately. Although epithelial-mesenchymal transition
is usually characterized by the loss of cell adhesion proteins,
myoepithelial cells, epithelial to mesenchymal transition-derived
cells, genuine mesenchymal cells still share common markers [46],
for instance CD29, making it difficult to ascertain if EMT has truly
taken place. A definitive surface marker for epithelial cells would
be helpful for dual-sorting alongside CD29 before culture might be
useful in establishing EMT in the various culture systems involving
the heterogenous cellular component of HBM.
We have previously demonstrated that the expression of nestin in
WCP co-segregated with cells which can exclude Hoechst dye [21].
In this report, we affirmed the finding of SP in HBM in all 53
individuals. Comparisons made between the expressions of various
markers present on SP and NSP suggested a difference between the
two populations. The finding of primitive markers EPCAM and
nestin and the lower expression of the mature epithelial marker
CK18 in the SP fraction of WCP suggest the possibility of the
presence of MaSC. While we were able to sort out cells that express
stem cell markers; namely the side-population as well as CD133 cell
surface marker, the failure to demonstrate self-renewal in current
culture conditions including the well described mammosphere
system suggest that they are unlikely to be mammary stem cells.
However, this could still be due to the inefficiencies of the current
culture system, and may require an in vivo model to further this line
of investigations. While we are unable to conclusively state the
absence of MaSC in HBM, it is worthwhile noting that if they are
present, they do not conform to the established culture parameters
and may require a switch-on/off mechanism.
In our study, we demonstrated the possible presence of stem/
progenitor compartment of HBM. However, we were unable to
culture them despite employing a range of routinely used
established cell culture conditions, and may reflect sub-optimal
culture conditions. In conjunction with the recent isolation of
MSC in colostrums when cultured with human umbilical cord
blood serum [16], we propose that continued research in this
emerging area may lead to the identification of novel population of
stem cells in HBM. Further work with appropriate in vivo model
may shed more light in this area.
Materials and Methods
Samples collection and processing
Ethics Statement: All human tissue collection for research
purposes was approved by the Domain Specific Review Board of
National University Hospital. In all cases, patients gave separate
written consent for the use of the collected tissue.
Forty-one breastfeeding women (duration of lactation – 1 to 12
months) were recruited to participate in the study. All samples
were collected and processed within four hours of expression.
Umbilical cord blood was collected at normal deliveries at full
termpregnanciesand mono-nuclear cells recovered throughdensity
centrifugation, and used as controls for methylcellulose assays
(n=2).
Bone marrow derived human fetal MSC and mononuclear cells
from peripheral blood were isolated as previously described [47],
[48] were used as controls for RT-PCR.
Isolation of cellular component of human breast milk
Cells were isolated from breast milk by centrifugation at 400 g
for 10 min. The cellular component pelleted down was washed
thrice with RPMI before use in culture and molecular work.
Isolation of mono-nuclear cells from umbilical cord blood
Mononuclear cells from umbilical cord and peripheral blood
were isolated as follows.
The umbilical cord blood was diluted 4-fold with 1X PBS
(Gibco, Singapore), and layered over Ficoll 1077 (Invitrogen,
Singapore) and centrifuged at 400 g for 35 min in a swinging-
bucket rotor with the brakes off. The top layer of plasma was
removed before collecting the mononuclear cells at the interphase,
which were then washed twice with RPMI 1640 (Gibco).
Reverse transcription polymerase chain reaction
Whole RNA was extracted from cells using the RNAeasy kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The isolated DNAse-treated RNA was quantified
with a spectrophotometer (Beckman, CA, USA) and 1 mg reverse-
transcribed using Sensiscript RT kit (Qiagen) and oligo-dT18
primers (Proligo, Singapore) at 25uC for 15 min, 42uC for 60 min
and 72uC for 15 min. Negative controls, without reverse
transcriptase, were performed for each RNA sample to ensure
absence of DNA contamination. For PCR amplification reactions,
conditions used were 94uC for 2 min, 30–40 cycles of 94uC for
15 s, 60uC for 15 s, 72uC for 60 s and a final extension at 72uC for
4 min. The primers used for PCR amplification were as follows:
D-glyceraldehyde-3-phosphate dehydrogenase: 59AAGGACT-
CATGACCACAGTCCATG-39 and 59TTGATGGTACATGA-
CAAGGTGCGG-39; Nestin: 59- GGTCAGTTCCTGAAGTT-
CACTCAG-39 and 59-CCTAGTACTATCGGGATTCAGCT-
G-39; CK5: 59-CGACAAGGTGCGGTTCCTG-39 and 59G-
CAGATTGGCGCACTG-39; CK14: 59- GATGACTTCCGC-
ACCAAGTATGAG-39 and 59-TCAATCTCCAGGTTCTG-
CATGGTG-39; CK18: 59-AGAAATCTGAAGGCCAGCTTG-
GAG-39 and 59-TACCCTGCTTCTGCTGGCTTAATG-39;C -
D34: 59-GACACTGTGGACTTGGTCACCAG-39 and GAG-
GAGGAAGCCATGGAGATCAG-39; CD133: 59-CCAAGTT-
CTACCTCATGTTTGG-39 and 59-ACCAACAGGGAGATT-
GCAAAGC-39; Osteonectin: 59-ATTTGATGATGGTGCAGA-
GGAA-39 and 59-GGTGGTTCTGGCAGGGATTT-39; Alka-
line Phophatase: 59-CAGGCTGGAGATGGACAAGTTC-39 and
59-GGACCTGGGCATTGGTGTT-39; Osteopontin: 59-CCTG-
CCAGCAACCGAAGTT-39 and 59-CACTATCACCTCGGC-
CATCA-39; Musashi-1: 59-GTGTGAGGTGCTTAACCTATC-
AGC-39 and 59-ACAGATGTGGAGAGAAGAGACACC-39; Ne-
urofilament-M: 59-CTTCAGCCAGTCCTCGTCCC-39 and 59-
TCCTCCAGGTGGTCCGAGTC-39.
Flow cytometry
For the indirectly-labelled antibodies, cells were incubated with
5% bovine serum albumin (Sigma-Aldrich, Singapore), 20% goat’s
serum (Vector Laboratories, CA, USA) for 45 min at room
temperature. Cell samples used for staining of intracellular
antigens were fixed with 1 ml of methanol for 10 min at 220uC
and then incubated in blocking solution as above with 0.5%
Nonidet P40 (Roche, Basel, Switzerland) added before staining.
Cells were suspended in 100 ml of the blocking solution and 5 mlo f
the primary antibody is added. The cells were incubated for
30 min at room temperature before washing twice with staining
buffer (0.5% BSA/2 mM EDTA in 1X PBS) by centrifugation at
400 g for 5 min. Cells were resuspended and incubated for 15 min
at room temperature in the dark in 488 AlexaFluor-labelled goat
anti-mouse antibody:blocking solution (1:200). For directly
labelled antibodies, cells were suspended in 100 ml of staining
buffer and 10 ml of fluorochrome-labelled antibody added into the
suspension. After an incubation of 20 min in the dark, the cells
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resuspended in 1 ml staining buffer for analysis.
Analysis was carried out using CyanTM ADP analyzer
(Dakocytomation) and results analysed with Summit 4.2.
Fluorescent-activated cell sorting
Hoechst staining was performed as previously described [21].
Briefly, cells were washed from breast milk with warmed RPMI
(Gibco). Cells were then resuspended in RPMI with Hoechst
33342 (Sigma) at a final concentration of 2.5 mg/ml and incubated
for 1 hr at 37uC. In the control samples, verapamil (Sigma-
Aldrich) was added (final concentration, 50 mg/ml) and after
incubation, samples were washed and resuspended in HBSS
(Gibco) supplemented with 5% FBS. Cells were stained with 1 mg/
ml propidium iodide (Sigma-Aldrich) for viability studies.
Cells from breast milk were incubated with phycoerythin
conjugated CD133/2 antibody (Miltenyi, Bergisch Gladbach,
Germany), diluted 1:10 in staining buffer (0.5% BSA/2 mM
EDTA in 1X PBS). The cells are washed twice with staining buffer
after incubation for 20 min at 37uC. Isotype controls were in place.
Cells from HBM were suspended in 100 ml of the blocking
solution and 5 ml of Stro-1(Chemicon, MA, USA) is added. The
cells were incubated for 30 min at room temperature before
washing twice with staining buffer (0.5% BSA/2 mM EDTA in
1X PBS) by centrifugation at 400 g for 5 min. Cells were
resuspended and incubated for 15 min at room temperature in
the dark with AlexaFluor-488-labelled goat anti-mouse antibody:
blocking solution (1:200). Thereafter, the cells are washed once
with staining buffer before being incubated in staining buffer
supplemented with 5% FBS on ice until sorting is completed.
All samples were analyzed and sorted by flow cytometry using
FACSAria and the software, FACS diva (Becton Dickinson, NJ,
USA).
Cell culture
Mammosphere culture. Cells from breast milk as well as a
breast adenocarcinomoma cell line, MCF-7 were grown in a
serum-free mammary epithelial growth medium (Biowhittaker,
ME, USA), supplemented with B27 (Invitrogen), 20 ng/ml
epidermal growth factor (EGF) (Sigma-Aldrich), 20 ng/ml basic
fibroblast growth factor (bFGF) (BD Biosciences, NJ, USA) and
4 mg/ml heparin (Sigma-Aldrich). Cells were plated on ultralow
attachment plates at various densities of 1, 100, 1,000 and 3,000
cells per well of a 96 well plate. Varying concentrations of EGF
(20–100 ng/ml), bFGF (20–100 ng/ml), FBS (1–20%) and
conditioned medium (1–80%) were used in the optimisation of
mammosphere medium for culture.
Methylcellulose culture. Cells were placed in HSC-CFU
lite with Epo (Miltenyi) at 1,000 to 3,000 cells per ml as per
manufacturer’s instructions. Briefly, individual specimens were
mixed with 3 ml of methylcellulose containing bovine serum, stem
cell factor, granulocyte-macrophage colony-stimulating factor,
interleukins-3 and 6, erythropoietin, and plated in 35-mm tissue
culture dishes in duplicates for 2 weeks.
Mesenchymal growth medium (D10). Cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM)-Glutamax
(Gibco) supplemented with 10% FBS, 1X penicillin/
streptomycin (Gibco).
Colony-forming unit-fibroblast assay. Sorted cells were
cultured in D10 medium at a cell density of 4 cells per cm
2 as per
Zhang et al, [43] for two weeks, with medium change every three
days. Colonies formed are then visualised by staining with 3%
crystal violet in methanol for 10 minutes.
Bone differentiation medium. MSCs were plated at a cell
density of 2610
4 cells per cm
2 and cultured in D10 supplemented
with 10 mM b-glycerophosphate, 10
28M dexamethasone and
0.2 mM ascorbic acid for two weeks, with medium changed every
three to four days.
Von Kossa staining. Cells were washed gently with PBS
before being fixed with 4% formalin for one hour. After washing
twice with distilled water, the cells were stained with freshly made
silver nitrate (Sigma-Aldrich) for ten minutes in the dark, exposed to
sunlight for 30 minutes, before washing twice with distilled water.
Alizarin red staining. Cells were washed and fixed as above,
and stained with 40 mM alizarin red (pH 4.2) for ten minutes at
room temperature. Thereafter, they are washed thoroughly with
PBS until clear.
Statistical analysis
Parametric data are shown as mean6 SEM, and analyzed using
Student’s t-Tests. A p ,0.05 was considered significant.
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